{"article_id": "COO_q3_2021.txt", "article": ["moving to third - quarter results and reporting all percentages on a constant currency basis , consolidated revenues were $ 763 million , with coopervision at $ 558 million , up 20 % , and coopersurgical at $ 206 million , up 58 % .", "non-gaap earnings per share were $ 3.41 .", "for coopervision , our daily silicone hydrogel portfolio led the way with all 3 regions posting strong growth .", "within the regions , the americas grew 16 % , led by myday and clariti and continued improvement in patient flow .", "emea grew a healthy 24 % as consumer activity returned in the region , and we took share .", "1 in emea , and we 're seeing the benefits of increasing patient flow , so , we 'll continue investing to support the reopening activity happening in many of the european markets .", "asia pac grew 18 % , led by a slow but steady improvement in consumer activity .", "silicone hydrogel dailies grew 31 % and with myday and clariti both performing well .", "recent data shows that over 90 % of contact lens wearers over the age of 40 expect to continue wearing lenses with the biggest challenge being finding a good multifocal .", "our portfolio grew a robust 90 % this quarter to $ 18 million , with misight up 187 % to $ 5 million and ortho-k products up 68 % .", "we continue targeting $ 65 million in myopia management sales this year , including misight reaching $ 20 million .", "as an example , it 's estimated that over 80 % of high school kids are myopic , so , treating children at a younger age is of high importance in the country .", "we now have over 40,000 children wearing misight worldwide , and that number is growing quickly .", "additionally , the average age of a new misight wearer remains 11 , so , this treatment is bringing children into contact lenses at a much younger age .", "on a longer - term basis , the macro growth trends remained solid , with roughly 33 % of the world being myopic today , and that number is expected to increase to 50 % by 2050 .", "this was an outstanding quarter with record revenues of $ 206 million .", "fertility , in particular , continued to perform exceptionally well , growing 72 % year over year to $ 83 million .", "and with an addressable market opportunity of well over $ 1 billion and mid- to upper - single - digit growth , this is a great market for us .", "and that more than 100 million individuals worldwide suffer from infertility .", "within our office and surgical unit , we grew 50 % with paragard up 51 % and office and surgical medical devices up 49 % .", "for paragard , we implemented a roughly 6 % price increase toward the end of the quarter , which resulted in a buy - in of roughly $ 4 million .", "to wrap up on coopersurgical , this was another excellent quarter , and it was great to exceed $ 200 million in sales for the first time ever .", "third - quarter consolidated revenues increased 32 % year over year or 28 % in constant currency to $ 763 million .", "consolidated gross margin increased year over year to 68.3 % , up from 66.3 % with coopervision posting higher margins driven by product mix and currency , and coopersurgical posting higher margins from product mix tied to the significant year - over - year growth in fertility and paragard .", "opex grew 28 % as sales increased with a rebound in revenues , along with higher sales and marketing expenses associated with investments in areas such as myopia management .", "consolidated operating margins were strong at 26.6 % , up from 23.2 % last year .", "interest expense was $ 5.6 million and the effective tax rate was 13.5 % .", "non-gaap earnings per share was $ 3.41 with roughly 49.8 million average shares outstanding .", "free cash flow was very strong at $ 180 million , comprised of $ 224 million of operating cash flow , offset by $ 44 million of capex .", "net debt decreased to $ 1.5 billion and our adjusted leverage ratio improved to one and a half times .", "specific to q4 , consolidated revenues are expected to range from $ 730 million to $ 760 million , up 7 % to 11 % in constant currency , with coopervision revenues between $ 540 million and $ 560 million up 6 % to 10 % in constant currency , and coopersurgical revenues between $ 190 million and $ 200 million , up 8.5 % to 14 % in constant currency .", "non-gaap earnings per share is expected to range from $ 3.24 to $ 3.44 .", "to provide color on this guidance , currency moves since last quarter have reduced the benefit of the full - year fx tailwind from 3 % to 2.5 % for revenues , and 7 % to 5 % for eps .", "with respect to q4 , this equates to reducing revenues by $ 10 million in coopervision and $ 2 million at coopersurgical , and reducing earnings per share by $ 0.14 .", "coopervision is offsetting some of the impact with expected strength in daily silicone and myopia management sales , while coopersurgical is expecting continued strength , although incorporating the q3 paragard buy - in of $ 4 million and hopefully some conservatism regarding covid 's impact on elective procedures .", "consolidated gross margins for the fiscal year are expected to be around 68 % , with fiscal q4 gross margins expected to be around 67.5 % , driven primarily by currency .", "our q4 tax rate is expected to be around 11 % .", "and lastly , our free cash flow continues to improve , and we 're now expecting roughly $ 550 million for the full year ."], "summary_gold": "q3 non -gaap earnings per share $ 3.41 .<q>sees q4 2021 non -gaap earnings per share $ 3.24 to $ 3.44 .<q>sees fiscal 2021 total revenue $ 2,893 - $ 2,923 million ( 16 % to 18 % constant currency ) .<q>sees fiscal q4 2021 total revenue $ 730 - $ 760 million ( 7 % to 11 % constant currency ) .", "summary_pred": "silicone hydrogel dailies grew 31 % and with myday and clariti both performing well .<q>to provide color on this guidance , currency moves since last quarter have reduced the benefit of the full - year fx tailwind from 3 % to 2.5 % for revenues , and 7 % to 5 % for eps .<q>within our office and surgical unit , we grew 50 % with paragard up 51 % and office and surgical medical devices up 49 % .<q>for paragard , we implemented a roughly 6 % price increase toward the end of the quarter , which resulted in a buy - in of roughly $ 4 million .<q>additionally , the average age of a new misight wearer remains 11 , so , this treatment is bringing children into contact lenses at a much younger age .<q>non-gaap earnings per share is expected to range from $ 3.24 to $ 3.44 .<q>net debt decreased to $ 1.5 billion and our adjusted leverage ratio improved to one and a half times .<q>we now have over 40,000 children wearing misight worldwide , and that number is growing quickly .<q>emea grew a healthy 24 % as consumer activity returned in the region , and we took share .<q>for coopervision , our daily silicone hydrogel portfolio led the way with all 3 regions posting strong growth .<q>this was an outstanding quarter with record revenues of $ 206 million .<q>and with an addressable market opportunity of well over $ 1 billion and mid- to upper - single - digit growth , this is a great market for us .<q>fertility , in particular , continued to perform exceptionally well , growing 72 % year over year to $ 83 million .<q>asia pac grew 18 % , led by a slow but steady improvement in consumer activity .<q>free cash flow was very strong at $ 180 million , comprised of $ 224 million of operating cash flow , offset by $ 44 million of capex .<q>and that more than 100 million individuals worldwide suffer from infertility .", "len_article": 38, "len_summary_gold": 4, "len_summary_pred": 16, "len_sent_scores": 38}